Literature DB >> 16261289

Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single nucleotide polymorphisms among Arabs.

Wassim Y Almawi1, Sose H Keleshian, Lobna Borgi, Naglaa A Fawaz, Nisreen Abboud, Nabil Mtiraoui, Touhami Mahjoub.   

Abstract

BACKGROUND: Factor V G1691A (FV-Leiden) and prothrombin (PRT) G20210A single nucleotide polymorphisms (SNPs) are major inherited risk factors of venous thromboembolism. In view of the heterogeneity in their world distribution and lack of sufficient information about their distribution among Arabs, we addressed the prevalence of both SNPs in 4 distinct Arab populations (Lebanon, Tunisia, Bahrain, and Saudi Arabia).
METHODS: Study subjects comprised 698 Lebanese, 313 Tunisian, 194 Bahraini, and 149 Saudi Arabian healthy subjects; genotyping was done by PCR-RFLP using Mnl I and Hind III for FV-Leiden and PRT G20210A, respectively.
RESULTS: The prevalence of the mutant A alleles of FV-Leiden and PRT G20210A were significantly higher among Lebanese (0.0788 and 0.0136) and Tunisians (0.0351 and 0.0128), as compared to Bahraini (0.0155 and 0.0052) and Saudi (0.0101 and 0.000) subjects. Higher frequency of the FV-Leiden G/A and A/A genotypes were seen in Lebanon (13.8 and 1.0%), followed by Tunisia (5.8 and 0.6%), Bahrain (3.1 and 0.0%) and Saudi Arabia ((2.0 and 0.0%). All PRT G20210A positive cases were in the heterozygote (G/A) state, and these comprised 3.6% for Lebanon, 2.6% for Tunisia, 1.0% for Bahrain. The carrier rate of FV-Leiden was significantly higher among Lebanese compared to the other populations (p < 0.001), while the difference in the prevalence of FV-Leiden between the other populations was not statistically different. With the exception of Lebanese-Saudi (p = 0.038), the prevalence of PRT G20210A was similar among the study communities. Furthermore, the overall average genetic differentiation between populations (estimated with the F(ST)) was 0.0022 for FV-Leiden and 0.005 for PRT G20210A.
CONCLUSIONS: These results further confirm the heterogeneity in FV-Leiden and PRT G20210A distribution among Arabs, and recommend potential institution of prophylactic measures for carriers of either or both SNPs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16261289     DOI: 10.1007/s11239-005-3550-4

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  33 in total

1.  High prevalence of factor V Leiden in healthy Jordanian Arabs.

Authors:  A Awidi; M Shannak; A Bseiso; M A Kailani; M A Kailani; N Omar; B Anshasi; N Sakarneh
Journal:  Thromb Haemost       Date:  1999-04       Impact factor: 5.249

2.  Born to clot: the European burden.

Authors:  D C Rees; N H Chapman; M T Webster; J F Guerreiro; J Rochette; J B Clegg
Journal:  Br J Haematol       Date:  1999-05       Impact factor: 6.998

3.  Absence of factor V Leiden mutation and low prothrombin G 20210 A mutation prevalence in a healthy Moroccan population.

Authors:  Florence Mathonnet; Sellama Nadifi; Valérie Serazin-Leroy; Mbarka Dakouane; Yves Giudicelli
Journal:  Thromb Haemost       Date:  2002-12       Impact factor: 5.249

4.  No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age.

Authors: 
Journal:  Circulation       Date:  2003-03-04       Impact factor: 29.690

5.  Factor V gene G1691A mutation, prothrombin gene G20210A mutation, and MTHFR gene C677T mutation are not risk factors for pulmonary thromboembolism in Chinese population.

Authors:  Yanhui Lu; Yanfen Zhao; Guozhang Liu; Xiaoling Wang; Zhihong Liu; Baiping Chen; Rutai Hui
Journal:  Thromb Res       Date:  2002-04-01       Impact factor: 3.944

Review 6.  Venous thrombosis: a multicausal disease.

Authors:  F R Rosendaal
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

7.  Prevalence of factor V G1691A (factor V-Leiden) and prothrombin G20210A gene mutations in a recurrent miscarriage population.

Authors:  Ramzi R Finan; Hala Tamim; Ghada Ameen; Huda E Sharida; Mooza Rashid; Wassim Y Almawi
Journal:  Am J Hematol       Date:  2002-12       Impact factor: 10.047

8.  Factor V Leiden and prothrombin G20210A mutations in Thai patients awaiting kidney transplant.

Authors:  Pasra Arnutti; Oytip Nathalang; Suwanna Cowawintaweewat; Wichai Prayoonwiwat; Punbupa Choovichian
Journal:  Southeast Asian J Trop Med Public Health       Date:  2002-12       Impact factor: 0.267

Review 9.  Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.

Authors:  B Dahlbäck
Journal:  Semin Hematol       Date:  1997-07       Impact factor: 3.851

10.  Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.

Authors:  T W Kim; W K Kim; J H Lee; S B Kim; S W Kim; C Suh; K H Lee; J S Lee; E J Seo; H S Chi; S H Kim
Journal:  J Korean Med Sci       Date:  1998-12       Impact factor: 2.153

View more
  16 in total

1.  Prevalence of the prothrombin G20210A polymorphism in the Lebanese population: use of a reverse hybridization strip assay approach.

Authors:  Amira S Sabbagh; Georges Ibrahim; Ziad Kanaan; Dina M R Shammaa; Rabab Abdel Khalek; Mona Ghasham; Layal Greige; Rami A R Mahfouz
Journal:  Mol Biol Rep       Date:  2007-12-08       Impact factor: 2.316

2.  Prevalence of factor V Leiden (G1691A) and prothrombin (G20210A) among Kurdish population from Western Iran.

Authors:  Zohreh Rahimi; Asad Vaisi-Raygani; Hadi Mozafari; Hadi Kharrazi; Mansour Rezaei; Ronald L Nagel
Journal:  J Thromb Thrombolysis       Date:  2007-08-14       Impact factor: 2.300

3.  Factor V Leiden, prothrombin 20210G>A, MTHFR 677C>T and 1298A>C, and homocysteinemia in Tunisian blood donors.

Authors:  Samira Hadhri; Mohamed Ben Rejab; Hajer Guedria; Lamia Ifa; Noureddine Chatti; Hadef Skouri
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

4.  Thrombophilic gene polymorphism studies in G6PD deficient individuals from Saudi population.

Authors:  Khalid K Alharbi; Imran Ali Khan; Rabbani Syed
Journal:  Bioinformation       Date:  2012-12-19

5.  Polymorphisms in Factor II and Factor V thrombophilia genes among Circassians in Jordan.

Authors:  R Dajani; A Arafat; N Hakooz; Z Al-Abbadi; Al-Motassem Yousef; M El Khateeb; F Quadan
Journal:  J Thromb Thrombolysis       Date:  2013-01       Impact factor: 2.300

6.  Race differences in the prevalence of the factor V Leiden mutation in Kuwaiti nationals.

Authors:  Ali A Dashti; Mehrez M Jadaon
Journal:  Mol Biol Rep       Date:  2010-11-21       Impact factor: 2.316

7.  High prevalence of three prothrombotic polymorphisms among Palestinians: factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase C677T.

Authors:  Ayman S Hussein
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

8.  Prevalence of factor V Leiden in south Tunisian blood donors.

Authors:  Lobna Maalej; Basma Hadjkacem; Ikram Ben Amor; Mariem Smaoui; Ali Gargouri; Jalel Gargouri
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

9.  Prevalence of coagulation factor II G20210A and factor V G1691A Leiden polymorphisms in Chechans, a genetically isolated population in Jordan.

Authors:  Rana Dajani; Raja Fatahallah; Abdelrahman Dajani; Mohammad Al-Shboul; Yousef Khader
Journal:  Mol Biol Rep       Date:  2012-06-29       Impact factor: 2.316

10.  Thrombophilic mutations among Southern Iranian patients with sickle cell disease: high prevalence of factor V Leiden.

Authors:  Zohreh Rahimi; Asad Vaisi-Raygani; Ronald L Nagel; Adriana Muniz
Journal:  J Thromb Thrombolysis       Date:  2007-07-11       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.